UA63032C2 - Drug for treating hypertension - Google Patents
Drug for treating hypertension Download PDFInfo
- Publication number
- UA63032C2 UA63032C2 UA2001096336A UA2001096336A UA63032C2 UA 63032 C2 UA63032 C2 UA 63032C2 UA 2001096336 A UA2001096336 A UA 2001096336A UA 2001096336 A UA2001096336 A UA 2001096336A UA 63032 C2 UA63032 C2 UA 63032C2
- Authority
- UA
- Ukraine
- Prior art keywords
- group
- hypertension
- forms
- biolabile
- symptomatic
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 title abstract description 4
- 229940079593 drug Drugs 0.000 title abstract description 4
- 150000002148 esters Chemical class 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 241000124008 Mammalia Species 0.000 claims abstract description 7
- -1 cyclopentylcarbonylamino group Chemical group 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 41
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 239000013543 active substance Substances 0.000 claims description 13
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000019622 heart disease Diseases 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 7
- 125000004043 oxo group Chemical group O=* 0.000 abstract description 4
- NTQSYIWTDXTRGG-UHFFFAOYSA-N 2-(1-benzazepin-1-yl)acetic acid Chemical class OC(=O)CN1C=CC=CC2=CC=CC=C12 NTQSYIWTDXTRGG-UHFFFAOYSA-N 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 description 21
- 230000007954 hypoxia Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 230000002685 pulmonary effect Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 210000005241 right ventricle Anatomy 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 230000004872 arterial blood pressure Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 229920002261 Corn starch Polymers 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 210000005240 left ventricle Anatomy 0.000 description 5
- 210000001147 pulmonary artery Anatomy 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000007530 Essential hypertension Diseases 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 3
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 230000000414 obstructive effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002236 anti-hypertrophic effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ZRVKEVKIXFZQMC-UHFFFAOYSA-N 2-(azepin-1-yl)acetic acid Chemical compound OC(=O)CN1C=CC=CC=C1 ZRVKEVKIXFZQMC-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- SYAKTDIEAPMBAL-UHFFFAOYSA-N aminorex Chemical compound O1C(N)=NCC1C1=CC=CC=C1 SYAKTDIEAPMBAL-UHFFFAOYSA-N 0.000 description 1
- 229950002544 aminorex Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 150000008038 benzoazepines Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19906310A DE19906310A1 (de) | 1999-02-16 | 1999-02-16 | Arzneimittel zur Behandlung von Bluthochdruck |
| PCT/EP2000/001068 WO2000048601A1 (de) | 1999-02-16 | 2000-02-10 | Arzneimittel zur behandlung von bluthochdruck |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA63032C2 true UA63032C2 (en) | 2004-01-15 |
Family
ID=7897580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2001096336A UA63032C2 (en) | 1999-02-16 | 2000-10-02 | Drug for treating hypertension |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6482820B2 (cs) |
| EP (1) | EP1154777B1 (cs) |
| JP (1) | JP2002537258A (cs) |
| KR (2) | KR100797665B1 (cs) |
| CN (1) | CN1198619C (cs) |
| AR (1) | AR036864A1 (cs) |
| AT (1) | ATE295174T1 (cs) |
| AU (1) | AU773240C (cs) |
| BR (1) | BR0008260A (cs) |
| CA (1) | CA2362273C (cs) |
| CZ (1) | CZ301499B6 (cs) |
| DE (2) | DE19906310A1 (cs) |
| DZ (1) | DZ3014A1 (cs) |
| ES (1) | ES2238268T3 (cs) |
| HK (1) | HK1042247B (cs) |
| HU (1) | HUP0105491A3 (cs) |
| IL (1) | IL144622A (cs) |
| NO (1) | NO329588B1 (cs) |
| NZ (1) | NZ514058A (cs) |
| PL (1) | PL195283B1 (cs) |
| PT (1) | PT1154777E (cs) |
| RU (1) | RU2270679C2 (cs) |
| SK (1) | SK287254B6 (cs) |
| TR (1) | TR200102386T2 (cs) |
| TW (1) | TWI221770B (cs) |
| UA (1) | UA63032C2 (cs) |
| WO (1) | WO2000048601A1 (cs) |
| ZA (1) | ZA200105828B (cs) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
| DK1234025T3 (da) * | 1999-11-19 | 2008-11-17 | Solvay Pharm Bv | Humane enzymer fra metalloproteasefamilien |
| CA2357833C (en) * | 2000-10-04 | 2005-11-15 | Warner-Lambert Company | Treatment of pulmonary hypertension using vasopressin antagonist |
| WO2002094176A2 (en) * | 2001-05-18 | 2002-11-28 | Solvay Pharmaceuticals Gmbh | Use of compounds with combined nep/mp-inhibitory activity on the preparation of medicaments |
| PT1448567E (pt) * | 2001-09-10 | 2010-03-12 | Tibotec Pharm Ltd | Método de preparação de hexa-hidro-furo[2,3-b]furan-3-ol |
| JP4384495B2 (ja) | 2002-01-16 | 2009-12-16 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | 固体のベンズアゼピン化合物の塩および医薬化合物の調製におけるそれらの使用 |
| AR038681A1 (es) * | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua |
| WO2004062692A1 (en) * | 2003-01-13 | 2004-07-29 | Solvay Pharmaceuticals B.V. | Formulation of poorly water-soluble active substances |
| SA04250283B1 (ar) * | 2003-09-26 | 2008-05-26 | سولفاي فارماسيتيكالز جي أم بي أتش | مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid |
| US7452875B2 (en) | 2003-09-26 | 2008-11-18 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| US7262184B2 (en) | 2003-09-26 | 2007-08-28 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| US7427611B2 (en) | 2003-09-26 | 2008-09-23 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| AU2004290925B2 (en) | 2003-11-18 | 2010-07-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients |
| US20050267072A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction |
| US20050267124A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors |
| US20050288272A1 (en) * | 2004-06-23 | 2005-12-29 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists |
| CN101080232A (zh) | 2004-12-15 | 2007-11-28 | 索尔瓦药物有限公司 | 包含NEP－抑制剂、内源性内皮素产生系统的抑制剂和HMG CoA还原酶抑制剂的药物组合物 |
| US20060205625A1 (en) * | 2005-02-18 | 2006-09-14 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics |
| US20070292503A1 (en) * | 2006-06-16 | 2007-12-20 | Gorissen Henricus R | Oral pharmaceutical composition of poorly water-soluble active substance |
| US20070299054A1 (en) * | 2006-06-22 | 2007-12-27 | Rajesh Jain | Oral pharmaceutical composition of a poorly water-soluble active agent |
| CN101969974A (zh) * | 2008-01-31 | 2011-02-09 | 范德比尔特大学 | 对于肺部病症的治疗 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0254032A3 (en) * | 1986-06-20 | 1990-09-05 | Schering Corporation | Neutral metalloendopeptidase inhibitors in the treatment of hypertension |
| US4749688A (en) * | 1986-06-20 | 1988-06-07 | Schering Corporation | Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension |
| CA1337400C (en) * | 1987-06-08 | 1995-10-24 | Norma G. Delaney | Inhibitors of neutral endopeptidase |
| US5087702A (en) * | 1991-01-30 | 1992-02-11 | Merck & Co., Inc. | Microbial transformation process for producing an antihypertensive product |
| US5362727A (en) * | 1993-07-26 | 1994-11-08 | Bristol-Myers Squibb | Substituted azepino[2,1-a]isoquinoline compounds |
| DE19510566A1 (de) * | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE19638020A1 (de) * | 1996-09-18 | 1998-03-19 | Solvay Pharm Gmbh | Die gastrointestinale Durchblutung fördernde Arzneimittel |
-
1999
- 1999-02-16 DE DE19906310A patent/DE19906310A1/de not_active Ceased
-
2000
- 2000-01-20 AR ARP000100257A patent/AR036864A1/es unknown
- 2000-01-21 TW TW089101041A patent/TWI221770B/zh not_active IP Right Cessation
- 2000-02-10 ES ES00903681T patent/ES2238268T3/es not_active Expired - Lifetime
- 2000-02-10 CZ CZ20012672A patent/CZ301499B6/cs not_active IP Right Cessation
- 2000-02-10 TR TR2001/02386T patent/TR200102386T2/xx unknown
- 2000-02-10 JP JP2000599393A patent/JP2002537258A/ja active Pending
- 2000-02-10 CA CA2362273A patent/CA2362273C/en not_active Expired - Fee Related
- 2000-02-10 WO PCT/EP2000/001068 patent/WO2000048601A1/de not_active Application Discontinuation
- 2000-02-10 SK SK1082-2001A patent/SK287254B6/sk not_active IP Right Cessation
- 2000-02-10 DE DE50010284T patent/DE50010284D1/de not_active Expired - Lifetime
- 2000-02-10 EP EP00903681A patent/EP1154777B1/de not_active Expired - Lifetime
- 2000-02-10 AU AU25476/00A patent/AU773240C/en not_active Ceased
- 2000-02-10 HK HK02104121.2A patent/HK1042247B/zh not_active IP Right Cessation
- 2000-02-10 PT PT00903681T patent/PT1154777E/pt unknown
- 2000-02-10 AT AT00903681T patent/ATE295174T1/de active
- 2000-02-10 HU HU0105491A patent/HUP0105491A3/hu unknown
- 2000-02-10 RU RU2001124604/15A patent/RU2270679C2/ru not_active IP Right Cessation
- 2000-02-10 KR KR1020077001387A patent/KR100797665B1/ko not_active Expired - Fee Related
- 2000-02-10 BR BR0008260-0A patent/BR0008260A/pt not_active Application Discontinuation
- 2000-02-10 PL PL00350167A patent/PL195283B1/pl not_active IP Right Cessation
- 2000-02-10 CN CNB008038236A patent/CN1198619C/zh not_active Expired - Fee Related
- 2000-02-10 KR KR1020017009705A patent/KR20010101922A/ko not_active Ceased
- 2000-02-10 NZ NZ514058A patent/NZ514058A/en not_active IP Right Cessation
- 2000-02-13 DZ DZ000029A patent/DZ3014A1/xx active
- 2000-10-02 UA UA2001096336A patent/UA63032C2/uk unknown
-
2001
- 2001-07-16 ZA ZA200105828A patent/ZA200105828B/en unknown
- 2001-07-30 IL IL144622A patent/IL144622A/en not_active IP Right Cessation
- 2001-08-15 NO NO20013958A patent/NO329588B1/no not_active IP Right Cessation
- 2001-08-16 US US09/930,186 patent/US6482820B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA63032C2 (en) | Drug for treating hypertension | |
| JP2002539154A (ja) | ベンゾインデンプロスタグランジンの吸入送達法 | |
| JP2002537258A5 (cs) | ||
| KR0158870B1 (ko) | 폐순환 승압의 치료, 예방 또는 진단용 조성물 | |
| JPH0531524B2 (cs) | ||
| JPH02326B2 (cs) | ||
| WO1994005290A1 (en) | Platelet aggregation inhibitor | |
| KR100260479B1 (ko) | 혈압강하용 복합제제 | |
| JPH0296537A (ja) | プロタミンの使用における有害作用の予防または減少用組成物 | |
| US4298611A (en) | Process for reducing blood pressure in animals | |
| Loukanov et al. | Animal models related to congenital heart disease and clinical research in pulmonary hypertension | |
| JP2532918B2 (ja) | グアニジノ安息香酸誘導体を有効成分として含有する抗動脈硬化剤 | |
| JPS6213926B2 (cs) | ||
| EP0717625B1 (en) | A method of treating liver disease and like indications with vasodilating agents | |
| KR970009076B1 (ko) | 디하이드로피리딘 화합물을 함유하는 정맥 신전도 증진제 및 심장 비대 억제제 | |
| WO1999004783A1 (en) | Composition for protection from damage by ischemia | |
| Adachi | Effects of E4080, a novel bradycardic agent with a coronary vasodilating property, on coronary and systemic hemodynamics in conscious dogs. | |
| JPH03130227A (ja) | カリウム低減・排泄剤 | |
| AU7647294A (en) | A method of treating liver disease and like indications with vasodilating agents | |
| MXPA01008164A (en) | Medicament for treating hypertension | |
| HK1003422B (en) | A method of treating liver disease and like indications with vasodilating agents |